| 2025 | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 1,2 M € | +1319.3% | 85,5 k € | -1.1% | 86,4 k € | — | — | — | |||||||||
| Gross margin | 1,3 M € | +26.8% | 991,8 k € | +8.1% | 917,2 k € | +103.3% | 451,1 k € | +190.4% | 155,3 k € | +222.6% | -126,7 k € | +2.4% | -129,8 k € | -82.6% | -71,0 k € | -54.6% | -46,0 k € | -417.4% | -8,9 k € | +28.0% | -12,3 k € | |
| EBITDA | 531,9 k € | +914.5% | -65,3 k € | +44.1% | -116,8 k € | +54.7% | -258,1 k € | +39.0% | -423,0 k € | -46.7% | -288,3 k € | -30.3% | -221,3 k € | -35.0% | -163,9 k € | -169.8% | -60,8 k € | -583.9% | -8,9 k € | +28.0% | -12,3 k € | |
| Operating profit | -102,1 k € | +81.7% | -558,6 k € | +18.5% | -685,8 k € | -13.7% | -603,1 k € | -8.0% | -558,6 k € | -85.8% | -300,6 k € | -33.1% | -225,8 k € | -36.9% | -165,0 k € | -169.3% | -61,3 k € | -589.6% | -8,9 k € | +28.0% | -12,3 k € | |
| Profit/loss | -444,1 k € | +51.4% | -913,7 k € | +2.5% | -936,7 k € | -22.8% | -762,5 k € | -21.2% | -629,1 k € | -93.6% | -325,0 k € | -26.2% | -257,5 k € | -38.6% | -185,8 k € | -802.4% | 26,4 k € | +237.0% | -19,3 k € | -56.2% | -12,4 k € | |
| Equity | 4,3 M € | +228.2% | 1,3 M € | -30.4% | 1,9 M € | +144.9% | 760,8 k € | -50.1% | 1,5 M € | -40.5% | 2,6 M € | +12.6% | 2,3 M € | +778.7% | 259,0 k € | -41.8% | 444,8 k € | +16.8% | 380,8 k € | +311.1% | 92,6 k € | |
| Total assets | 11,1 M € | +7.8% | 10,3 M € | +5.3% | 9,8 M € | +25.2% | 7,8 M € | +24.1% | 6,3 M € | +40.2% | 4,5 M € | +44.0% | 3,1 M € | +72.8% | 1,8 M € | +37.9% | 1,3 M € | +108.3% | 628,4 k € | +224.8% | 193,5 k € | |
| Cash | 389,0 k € | +86.7% | 208,4 k € | -61.1% | 535,3 k € | -11.3% | 603,1 k € | -41.2% | 1,0 M € | -10.9% | 1,2 M € | +7.8% | 1,1 M € | +367.6% | 228,3 k € | -13.4% | 263,6 k € | -5.6% | 279,2 k € | +175.3% | 101,4 k € | |
| Debts | 6,9 M € | -23.7% | 9,0 M € | +13.6% | 7,9 M € | +12.1% | 7,1 M € | +47.7% | 4,8 M € | +147.4% | 1,9 M € | +128.9% | 843,6 k € | -45.2% | 1,5 M € | +78.0% | 864,4 k € | +249.1% | 247,6 k € | +145.5% | 100,9 k € | |
| Staff | 8,7 | 9,4 | 9,2 | 8,2 | 7 | 1,3 | 1,3 | 1,8 | 1,8 | — | — | |||||||||||
Public limited company · Seraing · incorporated on 16/10/2013 · 8,7 ETP
Public limited company loss-making in the latest fiscal year. Cash position rising (+86.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
AQUILON PHARMACEUTICALS is a Public limited company incorporated in 2013. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Seraing. It employs on average 8,7 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette